Form 4: Cidara Director's Options Cashed Out in Merck Merger

Director Theodore R. Schroeder's stock options in Cidara Therapeutics were converted to cash following the company's acquisition by Merck Sharp & Dohme LLC.

Summary

• Theodore R. Schroeder, a Director of Cidara Therapeutics, Inc. (CDTX), reported changes in his beneficial ownership of derivative securities.
• Cidara Therapeutics, Inc. was acquired by Merck Sharp & Dohme LLC through its wholly-owned subsidiary, Caymus Purchaser, Inc., with the merger completed on January 7, 2026.
• Prior to and contingent upon the merger's effective time, all outstanding stock options held by Mr. Schroeder became fully vested and exercisable.
• Unexercised options were cancelled at the effective time of the merger and converted into a cash payment.
• The cash payment for each option was calculated as the product of the total number of common shares subject to the option multiplied by the excess of $221.50 per Common Share over the option's exercise price.
• The exercise prices and number of securities reported reflect a 1-for-20 reverse stock split effected by Cidara Therapeutics on April 24, 2024.

Sentiment

Score: 8

Explanation: The filing details the successful completion of a merger where Cidara Therapeutics was acquired by Merck, resulting in the cash conversion of outstanding stock options for the reporting person. This represents a positive liquidity event for option holders and a successful acquisition for the company's shareholders.

Positives

• Stock options held by Director Theodore R. Schroeder became fully vested and exercisable, providing immediate value.
• Options were converted into a cash payment, offering liquidity to the option holder.
• The merger price of $221.50 per Common Share indicates a significant valuation for Cidara Therapeutics, Inc. shareholders and option holders.

Negatives

• The filing does not explicitly state any negatives for the reporting person or the company, as it details the successful completion of a merger and the subsequent cash conversion of options.

Risks

• No specific risks are mentioned in this Form 4, which reports a completed transaction rather than ongoing operations or future uncertainties.

Future Outlook

The filing reports a completed merger, indicating that Cidara Therapeutics, Inc. is now a wholly-owned subsidiary of Merck Sharp & Dohme LLC. No forward-looking statements regarding the combined entity or its future operations are provided in this specific Form 4.

Industry Context

The acquisition of Cidara Therapeutics by Merck Sharp & Dohme LLC is consistent with broader trends in the biotechnology and pharmaceutical industries, where larger pharmaceutical companies often acquire smaller biotech firms to enhance their drug pipelines, gain access to innovative technologies, or expand their market presence. Such mergers are a common strategy for growth and portfolio diversification.

Comparison to Industry Standards

• The acquisition price of $221.50 per Common Share would typically be evaluated against Cidara's pre-merger stock price, analyst price targets, and valuations of comparable companies or assets in the biotechnology sector to determine the premium paid.
• Mergers and acquisitions are a standard mechanism for value realization in the biotech industry, particularly for companies with promising clinical assets or platforms. The specific terms of the deal, including the cash conversion of options, align with common practices in such transactions.

Corporate Governance

Stakeholder Impact

• Shareholders: Cidara shareholders received $221.50 per Common Share as part of the tender offer, providing a clear exit and liquidity.
• Employees (including option holders): Employees holding stock options, such as the reporting person, received cash payouts for their vested and unexercised options, providing a financial benefit.
• Cidara Therapeutics as an entity: Ceased to be an independent public company, becoming a wholly-owned subsidiary of Merck, which will integrate its operations and assets into Merck's larger structure.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Merck, Merger, Acquisition, Stock Options, Form 4, Beneficial Ownership, Theodore R. Schroeder, Biotechnology, Pharmaceuticals